Ashkon Software



KIN - Kindred Biosciences, Inc.

Kindred Biosciences, Inc. logo Kindred Biosciences, Inc. (KIN) is a biopharmaceutical company that focuses on the development of novel therapies for pets. The company is headquartered in Burlingame, California, and was founded in 2012.

Kindred Biosciences is developing a pipeline of drugs for pets, including treatments for osteoarthritis, allergic dermatitis, and cancer. The company's lead product candidate is Mirataz, a transdermal gel formulation for the management of weight loss in cats. Mirataz received FDA approval in 2018 and is the first FDA-approved transdermal medication for cats.

The company's other product candidates include Zimeta, a non-steroidal anti-inflammatory drug for the control of fever in horses, and KIND-012, a monoclonal antibody for the treatment of atopic dermatitis in dogs. In addition, Kindred Biosciences is developing a pipeline of biosimilars and novel biologics for the treatment of a variety of animal diseases.

Kindred Biosciences is focused on providing innovative and effective therapies for pets and their owners. With a growing pipeline of product candidates and a commitment to scientific excellence, the company is well-positioned to make a significant impact on the animal healt




Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer